|
Parkinson Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
The selective inhibition of MAO-B suggests further investigations on acacetin 7-methyl as a potential new drug lead for the treatment of neurodegenerative disorders, including Parkinson's disease.
|
30813423 |
2019 |
|
Parkinson Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
Monoamine oxidase B (MAO B) inhibitors, which inhibit dopamine decomposition by antagonizing MAO B activity, are approved and widely used for clinical treatment of Parkinson's disease (PD).
|
30004136 |
2018 |
|
Parkinson Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
Synthesis and evaluation of biaryl derivatives for structural characterization of selective monoamine oxidase B inhibitors toward Parkinson's disease therapy.
|
29198609 |
2018 |
|
Parkinson Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
MAO-B inhibitors are currently widely used as symptomatic therapeutics for PD and, although somewhat controversial, these drugs may also exhibit disease-modifying properties.
|
29713806 |
2018 |
|
Parkinson Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
Conventional pharmacological treatment of PD is based on the replacement of dopamine using dopamine precursors (levodopa, L-DOPA, L-3,4 dihydroxyphenylalanine), dopamine agonists (amantadine, apomorphine) and MAO-B inhibitors (selegiline, rasagiline), which can be used alone or in combination with each other.
|
30214392 |
2018 |
|
Parkinson Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
Accordingly, symptomatic effects of MAO-B inhibition for a limited amelioration of impaired motor behaviour and wearing-off phenomena in patients with Parkinson's disease are well proven, even when MAO-B inhibitors are only applied together with dopamine agonists.
|
29569037 |
2018 |
|
Parkinson Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
The second MAO-B inhibitor approved for the treatment of Parkinson's disease, rasagiline also possesses this structural element and shows similar pharmacological characteristics.
|
29417334 |
2018 |
|
Parkinson Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
Rasagiline, an irreversible MAO-B inhibitor, is used to treat Parkinson's disease because of its neuroprotective effect and increasing central DA.
|
29956417 |
2018 |
|
Parkinson Disease
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
Our findings thus support that AEP-mediated cleavage of α-Syn at N103 is required for the association and activation of MAO-B, mediating PD pathogenesis.
|
29769405 |
2018 |
|
Parkinson Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
Zonisamide is an-anti-convulsant drug that has recently been shown to improve clinical symptoms of PD through its inhibition of monoamine oxidase B (MAO-B).
|
30017881 |
2018 |
|
Parkinson Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
MAO-B and COMT Genetic Variations Associated With Levodopa Treatment Response in Patients With Parkinson's Disease.
|
29578580 |
2018 |
|
Parkinson Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
This study suggests that quinazolinones are promising leads for the development of selective MAO-B inhibitors which may be used for the treatment of neurodegenerative disorders such as Parkinson's disease.
|
30279044 |
2018 |
|
Parkinson Disease
|
0.600 |
AlteredExpression
|
disease |
BEFREE |
We compared the standard uptake values of flortaucipir at regional and voxel levels in Parkinson's disease patients who received MAO-B inhibitors with those who did not.
|
29127552 |
2018 |
|
Parkinson Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
We performed a systematic literature search to identify randomized controlled trials assessing the efficacy of MAO-B inhibitors in patients with Parkinson's disease.
|
29847694 |
2018 |
|
Parkinson Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
The present study identified Garcinol as a potential candidate in the treatment paradigm of PD by virtue of its exorbitant MAO-B inhibitory potential.
|
30077198 |
2018 |
|
Parkinson Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
New 4-(3-nitrophenyl)thiazol-2-ylhydrazone derivatives are proposed as dual-target-directed monoamine oxidase B (MAO-B) and acetylcholinesterase (AChE) inhibitors, as well as antioxidant agents, for the treatment of neurodegenerative disorders such as Parkinson's disease.
|
29126727 |
2018 |
|
Parkinson Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
Nowadays, therapeutic attention on MAOIs engrosses two imperative categories; MAO-A inhibitors, in certain mental disorders such as depression and anxiety, and MAO-B inhibitors, in neurodegenerative disorders like Alzheimer's disease (AD) and Parkinson's disease (PD).
|
29335210 |
2018 |
|
Parkinson Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
As the monoamine oxidase B (MAO B) and the histamine H<sub>3</sub> receptor (H<sub>3</sub>R) are promising targets for dopaminergic regulation, we synthetized dual-targeting ligands (DTLs) as non-dopaminergic receptor approach for the treatment of PD.
|
29477889 |
2018 |
|
Parkinson Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
Rasagiline is a monoamine oxidase-B inhibitor used for Parkinson's disease (PD) treatment, but its effectiveness on Chinese patients is unclear.
|
30534374 |
2018 |
|
Parkinson Disease
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
The MAOB (rs1799836) polymorphism predicts putaminal dopamine turnover in early PD with the MAOB<sup>TT</sup> allele linked to high enzyme activity leading to higher intrinsic dopamine turnover, which has been demonstrated to constitute a risk factor for motor complications.© 2018 The Authors.
|
30216543 |
2018 |
|
Parkinson Disease
|
0.600 |
GeneticVariation
|
disease |
BEFREE |
Rasagiline, a monoamine oxidase B inhibitor with neuroprotective potential in Parkinson's disease, has shown a disease-modifying effect in the SOD1-Gly93Ala low-expressing mouse model of amyotrophic lateral sclerosis, both alone and in combination with riluzole.
|
29934198 |
2018 |
|
Parkinson Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
Extra-virgin olive oils (EVOOs) obtained from 'Brava' and 'Mansa', varieties recently identified from Galicia (northwestern Spain), were selected for in vitro screening to evaluate their capacity to inhibit key enzymes involved in Alzheimer's disease (AD) (acetylcholinesterase (AChE), butyrylcholinesterase (BuChE) and 5-lipoxygenase (5-LOX)), major depressive disorder (MDD) and Parkinson's disease (PD) (monoamine oxidases: <i>h</i>MAO-A and <i>h</i>MAO-B respectively).
|
29561824 |
2018 |
|
Parkinson Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
Accordingly, small-molecule MAO-B inhibitors potentially alleviate the symptoms of dopamine-linked neuropathologies such as depression or Parkinson's disease.
|
29552556 |
2018 |
|
Parkinson Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
The administration of the xanthines has been proposed as a non-dopaminergic strategy for neuroprotection in PD and the mechanisms of protection have been associated with antagonism of adenosine A2A receptors and monoamine oxidase type B (MAO-B) inhibition.
|
30129404 |
2018 |
|
Parkinson Disease
|
0.600 |
Biomarker
|
disease |
BEFREE |
Together, this study demonstrates that Taltirelin may exert neuroprotective effect <i>via</i> inhibiting MAO-B and reducing the oxidative stress and apoptosis, preventing AEP activation and its subsequent pathological cleavage of tau and α-synuclein, thus provides evidence for Taltirelin in protective treatment of PD.
|
30618632 |
2018 |